David White

Ed Arce

Len Levi

Sa'ar Yaniv

Thomas Yip

Vernon Bernardino

- Galimedix Therapeutics has **completed its Phase 1 study** for orally administered **GAL-101**, a small molecule designed to target misfolded amyloid beta monomers.  **[1133416_0a7d16660d804d6fb5cc1a35b8a20992_1]** 
- The study demonstrated that oral GAL-101 was **well tolerated and clinically safe**, with no serious adverse events, and effectively **crosses the blood-brain barrier**.  **[1133416_0a7d16660d804d6fb5cc1a35b8a20992_1]** **[1133416_0a7d16660d804d6fb5cc1a35b8a20992_0]** 
- The pharmacokinetic profile strongly supports advancing GAL-101 into **Phase 2 development for Alzheimer’s disease**, with a Phase 2 trial planned and fundraising initiated.  **[1133416_0a7d16660d804d6fb5cc1a35b8a20992_1]** **[1133416_0a7d16660d804d6fb5cc1a35b8a20992_0]** 
- Additionally, Galimedix is conducting a **partner-funded Phase 2 clinical trial** with GAL-101 eyedrops for dry age-related macular degeneration (dAMD).  **[1133416_0a7d16660d804d6fb5cc1a35b8a20992_1]** **[1133416_0a7d16660d804d6fb5cc1a35b8a20992_3]**

GALECTIN THERAPEUTICS (GALT)